NCT00799942View on ClinicalTrials.gov

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

PHASE2TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2009

Conditions
Nystagmus, CongenitalNystagmus, AcquiredMultiple Sclerosis
Interventions
DRUG

Neramexane mesylate

open-label treatment of 36 months Neramexane mesylate up to 75 mg per day

Trial Locations (1)

LE2 7LX

University of Leicester, Leicester Royal Infirmary, Ophthalmology Group, Leicester

Sponsors
All Listed Sponsors
lead

Merz Pharmaceuticals GmbH

INDUSTRY

NCT00799942 - Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus | Biotech Hunter | Biotech Hunter